# Lantheus Holdings, Inc. (LNTH) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_33267705b8cbafba77e5 · retrieved 2026-08-11T15:53:11.872Z

## Overview
Lantheus Holdings, Inc. is the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes.

Lantheus Holdings, Inc. entered into a definitive merger agreement on August 3, 2026 with Curium US Holdings LLC, under which Curium will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) providing for up to $12.00 per share in potential additional cash payments contingent on achievement of specified commercial milestones for Lantheus' products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. The Board of Directors of Lantheus has unanimously approved the transaction.

## Terms
- Counterparty: Curium US Holdings LLC · Deal value: $8.00B · Consideration: mixed · Price/share: $102.5

## Key dates
- Announced 2026-08-04 · Expiry 2027-05-02 · Expected close 2027-05-02

## Timeline
- 2026-08-04 · 8-K (0001193125-26-331138): 8-K - Lantheus Holdings, Inc. — *Lantheus Holdings, Inc. is a diagnostic imaging company that develops and commercializes radiodiagnostic products including PYLARIFY, DEFINITY, and Neuraceq, and is advancing a pipeline of oncology and neurology diagnostic agents.* On August 3, 2026, Lantheus Holdings, Inc. entered into a definitive merger agreement with Curium US Holdings LLC and its subsidiary Coco Merger Sub Inc., whereby Merger Sub will merge with and into Lantheus, with Lantheus surviving as a wholly owned subsidiary of Curium. Each outstanding share of Lantheus common stock will convert into $102.50 in cash per share plus one contingent value right (CVR) representing the right to receive up to $12.00 per share in cash upon achievement of specified commercial milestones related to the Global Prostate Cancer Diagnostics Franchise, Global Neurology Diagnostics Franchise, and Global DEFINITY Franchise. The transaction is not subject to a financing condition; Parent has obtained equity and debt financing commitments. Closing is expected by May 2, 2027 (the Outside Date), subject to customary closing conditions including stockholder approval and regulatory approvals under the Hart-Scott-Rodino Act and foreign direct investment laws.
  https://www.sec.gov/Archives/edgar/data/1521036/0001193125-26-331138.txt
- 2026-08-06 · 8-K (0001193125-26-336771): 8-K - Lantheus Holdings, Inc. — *Lantheus Holdings, Inc. is the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes.* Lantheus Holdings, Inc. entered into a definitive merger agreement on August 3, 2026 with Curium US Holdings LLC, under which Curium will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) providing for up to $12.00 per share in potential additional cash payments contingent on achievement of specified commercial milestones for Lantheus' products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. The Board of Directors of Lantheus has unanimously approved the transaction.
  https://www.sec.gov/Archives/edgar/data/1521036/0001193125-26-336771.txt

## Citations
- 0001193125-26-331138 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526331138
- 0001193125-26-336771 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526336771